Codexis, Inc.

Reimagine enzymes as transformational products

Enzymes can do more for our world - mitigate environmental threats, optimize research and diagnostic tools, and address unmet patient needs as innovative biotherapeutics. When enzymes are engineered and optimized for their target use, the final improved products and processes can be transformational.

Learn more about our technology

Biotherapeutics

Discovering and developing life-changing treatments for patients is our focus. By tailoring biotherapeutic performance using novel protein and gene therapies, we are well-positioned to address unmet medical needs and find treatments for a wide range of diseases and disorders. 

Learn More

Life Science Tools

Highly specialized enzymes can address many challenges faced in DNA and RNA synthesis, NGS, and clinical diagnostics. Whether it’s yield, accuracy, or sample conditions, engineered enzymes can help provide better results.

Learn More

Sustainable Manufacturing

Sustainable bioprocesses enabled by enzymes can eliminate the use of hazardous reagents, remove wasteful steps, and reduce overall manufacturing cost for API production, food ingredients production, and other industrial operations. Explore novel approaches that benefit the triple bottom line – social, environmental, and financial.

Everything we do is to improve health.
Of people and the planet.

At Codexis, we strive to discover and develop more effective therapeutics, offer healthier choices, innovate sustainable processes and products, and reduce waste – all to create a brighter future.

These goals are grand but not beyond reach. Together with our business partners and loyal customers, we can make them a reality.

Latest News

Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting

Codexis Reports First Quarter 2022 Financial Results

Codexis and seqWell Announce Strategic Investment and Partnership Initiation

Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis

Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria

Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing

Scientific Highlights

Enzymes for tailored insulin derivatives

A paper authored by Merck and Codexis in the June 2022 issue of the peer-reviewed journal Science, details the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates.

View Paper

There are many steps to a healthier future.

Join us on our journey.

Partner with us Join our team